Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company focused on iron deficiency treatment, has applied to the London Stock Exchange for admission to trading on AIM of 10,000,000 new ordinary shares of 1.5p each. The application represents an extension to the company's existing block listing and relates to its Retention and Performance Share Plan. Admission is expected to become effective on or around 25 November 2026, according to the announcement dated 20 November 2026.

Key Points

  • Shield Therapeutics plc (LSE: STX) — commercial-stage specialty pharmaceutical company focused on iron deficiency
  • Application made to admit 10,000,000 new ordinary shares of 1.5p each to trading on AIM under a block listing extension
  • Shares relate to the company's Retention and Performance Share Plan; admission expected on or around 25 November 2026
  • Investors should watch for confirmation of admission and any update on ACCRUFeR® commercial performance in the US market

Shield Therapeutics Seeks AIM Admission of 10 Million Shares Tied to Employee Share Plan

The announcement states that Shield Therapeutics has made a formal application to the London Stock Exchange for the admission to trading on AIM of 10,000,000 new ordinary shares of 1.5p each. These shares form part of an extension to the company's existing block listing and are connected to its Retention and Performance Share Plan. On exercise of the relevant options, the new ordinary shares will be credited as fully paid and will rank pari passu with the existing ordinary shares already in issue. Admission is anticipated to take effect on or around 25 November 2026.

ACCRUFeR® Holds Number-One Branded Prescription Oral Iron Position in the US Market

Shield Therapeutics markets ACCRUFeR®/FeRACCRU® (ferric maltol), described in the announcement as the first and only FDA-approved oral iron therapy to treat iron deficiency and iron deficiency anaemia. According to data cited from IQVIA Xponent PlanTrak, ACCRUFeR® is currently the number-one branded prescription oral iron in the US market. The announcement notes that iron deficiency and iron deficiency with anaemia together affect approximately 20 million people in the US, representing a stated market opportunity of $2.3 billion. The US launch includes paediatric patients aged 10 years and older.

International Licensing Partnerships Extend FeRACCRU® Reach Across Multiple Territories

Beyond the United States, Shield has licensed commercialisation rights across several regions. FeRACCRU® is marketed in the UK and European Union by Norgine B.V., covering paediatric patients aged 12 and older, with Norgine also holding rights in Australia and New Zealand. Additional licensing agreements cover Canada through Kye Pharmaceuticals, China, Hong Kong, Macau and Taiwan through Beijing Aosaikang Pharmaceutical, the Republic of Korea through Korea Pharma Co., Ltd., and Japan through Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. ACCRUFeR®/FeRACCRU® carries patent coverage until the mid-2030s.

Dilution Risk for Existing Shareholders as New Ordinary Shares Enter Circulation

The admission of 10,000,000 new ordinary shares will increase Shield's total share count, introducing a degree of dilution for existing shareholders. This is a standard consideration when employee share plans are exercised at commercial-stage companies. The new shares rank equally with existing shares in all respects once admitted. Investors may be watching whether the pace of share plan exercises reflects management and employee retention activity as the company continues to build its commercial presence in the competitive US oral iron therapy market.